Revolutionizing the Way the Body Responds to Injury

Xequel’s proprietary aCT1 peptide technology platform has extensive preclinical and clinical research to support multiple unique applications and formulations across therapeutic areas. We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

Dermatology

Cutaneous Radiation Injury (CRI)

Diabetic Foot Ulcer (DFU)

Venous Leg Ulcer (VLU)

Ophthalmology

Corneal
Injury

Retinal
Diseases

Pulmonology

Acute
Lung Injury
(ALI)

Acute Respiratory Distress Syndrome (ARDS)

Xequel Bio Pipeline

Revolutionizing the Way the Body Responds to Injury

Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate proper healing.

Dermatology

Granexin® Gel

Learn More

Ophthalmology

iNexin Eye Drops

Learn More

Pulmonology

aCT1 Inhalation Solution

Learn More

Contact us for collaborations or partnership opportunities.